Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).The analyst comments "Nurix announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Nurix (NRIX) trades up 20%, RBC says agreement with Roche removes some overhangs, 'We remain buyers'June 8, 2026 9:42 AM Form 8-K Nurix Therapeutics, Inc. For: Jun 06June 8, 2026 6:11 AM Nurix Therapeutics partners with Roche on BTK degrader drug dealJune 8, 2026 2:54 AM Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyJune 8, 2026 1:00 AM Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyJune 8, 2026 1:00 AM